
Poland to reimburse pirtobrutinib from January 2027
TV SourceTVN24Nov18 · Health
All of Warsaw
Warsaw
Warsaw

Poland’s National Health Fund will begin funding pirtobrutinib in January 2027. Deputy Health Minister Katarzyna Kacperczyk told the Sejm that the procedure for the drug had concluded with a positive decision.
Reimbursement will cover treatment of chronic lymphocytic leukemia and mantle cell lymphoma. The drug is a Bruton’s tyrosine kinase inhibitor intended primarily for patients whose previous therapy has stopped working.
Negotiations on other drugs for the January list are still under way. Pirtobrutinib was previously included in the expert TOP10 Hemato 2026 list of priority needs in Polish hemato-oncology.
Advertising 99.cleanwhale.pl
Loading…